GABA and glutamate systems as therapeutic targets in depression and mood disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Advances made in diverse areas of neuroscience suggest that neurotransmitter systems, additional to the monoaminergic, contribute to the pathophysiology of mood disorders. This ever accruing body of preclinical and clinical research is providing increased recognition of the contribution made by amino acid neurotransmitters to the neurobiology of mood disorders. This review examines evidence supporting the role of GABA and glutamate in these processes and explores the potential to target these systems in the development of novel compounds; the viability of these agents for treatment-related co-morbidities will also be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“According to the World Health Organization’s landmark 1996 publication, ‘The Global Burden of Disease,’ unipolar depression is the leading cause of disability for persons aged 15 – 44 years, with bipolar disorder ranking sixth [1,2].”
MethodAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932 · cited 1×
“Stress-responsive neurotoxicity has been implicated as the mechanism responsible for the hippocampal and cortical morphological [132-134], and histological [135-137] alterations that are associated with MDD.”
BackgroundHippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525 · cited 1×
“Stress-responsive neurotoxicity has been implicated as the mechanism responsible for the hippocampal and cortical morphological [132-134], and histological [135-137] alterations that are associated with MDD.”
BackgroundRajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477 · cited 1×
“Stress-responsive neurotoxicity has been implicated as the mechanism responsible for the hippocampal and cortical morphological [132-134], and histological [135-137] alterations that are associated with MDD.”
BackgroundFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“AP-7, MK-801, ACPC Competitive NMDA antagonist, non-competitive NMDA antagonist, partial agonist at strychnine-insensitive glycine receptors All three compounds mimicked the effects of clinically effective antidepressants in animal models commonly used to evaluate potential antidepressant activity [232]”
BackgroundCotter, D. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.4.386 · Cited by 634 · cited 1×
“Stress-responsive neurotoxicity has been implicated as the mechanism responsible for the hippocampal and cortical morphological [132-134], and histological [135-137] alterations that are associated with MDD.”
BackgroundSanacora, G., Mason, G. F., Rothman, D. L., Behar, K. L., Hyder, F., Petroff, O. A. C., Berman, R. M., Charney, D. S., & Krystal, J. H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.1043 · Cited by 627
Self-citationMoghaddam, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13387.x · Cited by 567
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Self-citationCalabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446 · cited 1×
“However, a series of double-blind placebo-controlled, trials did not find the medication effective as monotherapy or add-on therapy for mood disorders [75,76].”
BackgroundGlucocortcoids mediate the stress-induced extracellular accumulation of glutamate
Moghaddam, B., Bolinao, M. L., Stein-Behrens, B., & Sapolsky, R. (1994) · Brain Research · doi:10.1016/0006-8993(94)91622-5 · Cited by 378
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes
Hamidi, M., Drevets, W. C., & Price, J. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.006 · Cited by 369 · cited 1×
“It is notable, however, that in individuals with bipolar disorder, total oligodendrocyte numbers did not differ significantly from controls [138].”
BackgroundMonahan, J. B., Handelmann, G. E., Hood, W. F., & Cordi, A. A. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90571-6 · Cited by 257 · cited 1×
“Subsequent studies [179-182] have demonstrated that DCS acts like a partial agonist, producing roughly half of the maximal facilitation of NMDA receptor function associated with glycine at maximally stimulating doses.”
BackgroundPlasma and platelet excitatory amino acids in psychiatric disorders
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1731 · Cited by 243
Bagley, J., & Moghaddam, B. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00435-6 · Cited by 231 · cited 1×
“Stress increases extracellular glutamate concentrations [121-124], and alters NMDA and AMPA receptor binding”
BackgroundAntidepressant-like actions of an AMPA receptor potentiator (LY392098)
Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00194-5 · Cited by 225 · cited 3×
“Positive allosteric modulators of AMPA receptors are effective in animal models indicative of antidepressant activity [114], and hold promise for new approaches to cognitive enhancement [115].”
BackgroundLowy, M. T., Wittenberg, L., & Yamamoto, B. K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010268.x · Cited by 217 · cited 1×
“Stress increases extracellular glutamate concentrations [121-124], and alters NMDA and AMPA receptor binding”
BackgroundAltamura, C., Maes, M., Dai, J., & Meltzer, H. Y. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00033-l · Cited by 193
Increased serum glutamate in depressed patients
Kim, J. S., Schmid-Burgk, W., Claus, D., & Kornhuber, H. H. (1982) · Archiv f�r Psychiatrie und Nervenkrankheiten · doi:10.1007/bf00345492 · Cited by 189
Small-Dose Ketamine Improves the Postoperative State of Depressed Patients
Kudoh, A., Takahira, Y., Katagai, H., & Takazawa, T. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200207000-00020 · Cited by 189
Bai, F., Bergeron, M., & Nelson, D. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00104-7 · Cited by 144 · cited 1×
“Chronic treatment with this class of agents has been shown to increase progenitor cell proliferation in the dentate gyrus of the hippocampus, an anatomical region well known for both mood disorder and memory implications [204].”
Background
Cited by
Integrating neuroimmune systems in the neurobiology of depression
Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.69 · Cited by 668
Pathophysiology of depression: do we have any solid evidence of interest to clinicians?
HASLER, G. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00298.x · Cited by 604
Khairova, R. A., Machado-Vieira, R., Du, J., & Manji, H. K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009924 · Cited by 350
Hu, Y., Li, J., Liu, P., Chen, X., Guo, D.-H., Li, Q.-S., & Rahman, K. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/728342 · Cited by 311
Klempan, T. A., Sequeira, A., Canetti, L., Lalovic, A., Ernst, C., ffrench-Mullen, J., & Turecki, G. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002110 · Cited by 294
Metadata
- Authors
- Kendell, S. F., Krystal, J. H., & Sanacora, G.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2005-02
- Volume
- 9
- Issue
- 1
- Pages
- 153-168
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2128409156
- Cited by
- 150
- References
- 25
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.